Clinical trial
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
NCT03690869 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- September 24, 2018
- Completion date
- May 10, 2023
- Enrollment
- 57 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse intrinsic pontine glioma, high grade glioma, refractory central nervous system tumor, refractory solid tumor, relapsed central nervous system tumor, relapsed solid tumor